Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics

项目摘要 在有记载的历史中，人类一直将天然产物用于药用目的。开始的时间 现代分析和制药方法，这些“自然疗法”中的一些活性成分是 发现并成为药物开发工作中的基础化学品。在众多的例子中， 阿司匹林（杨柳树皮）、辣椒素（红辣椒）和阿片类药物（罂粟植物）因其 镇痛特性。与这些其他天然产品类似，大麻长期以来一直用于药用 目的，包括缓解疼痛。大麻植物（Cannabis sativa/indica）含有100多种 植物大麻素以及500多种其他已确定的化学物质，包括使大麻 独特的风味和香气。然而，除了2009-THC和CBD之外，在识别、分离和 以足以用于体内评价的量纯化少量植物大麻素阻碍了足够的 研究单个植物大麻素的潜在治疗用途。最近，我们获得了 通过专利生物合成工艺合成的纯化微量大麻素， 临床前体内试验。拟议项目的目标是提供一个全面的评价， 化合物单独和计划的组合，以确定它们作为镇痛剂的潜在功效。此外，本发明还提供了一种方法， 我们将对在大麻植物中发现的某些萜烯进行平行调查。小说 需要镇痛策略来对抗对阿片类药物的过度依赖及其导致的继发性后果 依赖性和发病率/死亡率。

PROJECT SUMMARY Throughout recorded history, humans have used natural products for medicinal purposes. With the onset of modern analytical and pharmaceutical methods, the active ingredients in some of these “natural remedies” were identified and became foundational chemicals in drug development efforts. Among the numerous examples, aspirin (bark of the willow tree), capsaicin (chili peppers), and opioids (opium poppy plant) are notable for their analgesic properties. Similar to these other natural products, Cannabis sativa has long been used for medicinal purposes, including pain relief. The cannabis plant (Cannabis sativa/indica) contains over 100 phytocannabinoids as well as over 500 other identified chemicals, including the terpenoids that give cannabis its distinctive flavoring and aroma. Beyond 9-THC and CBD, however, difficulties in identifying, isolating and purifying minor phytocannabinoids in quantities sufficient for in vivo evaluation have hampered adequate investigation of potential therapeutic uses of individual phytocannabinoids. Recently, we have secured access to purified minor cannabinoids synthesized via a patented biosynthetic process in quantities that allow for preclinical in vivo testing. The goal of the proposed project is to provide a comprehensive evaluation of these compounds alone, and in planned combinations, to determine their potential efficacy as analgesics. In addition, we will conduct a parallel investigation of selected terpenes that have been identified in the cannabis plant. Novel analgesic strategies are needed to combat over-reliance on opioids and the resulting secondary consequences of dependence and morbidity/mortality.